In the BICC1 low group, the combination therapy of Bevacizumab and GEM showed an enhanced effect on promoting vascular normalization and suppressing tumor growth, with decreased tumor volumes and microvessel density, as compared to GEM alone, while the anti-LCN2 antibody did not further enhance the therapeutic efficacy of GEM. The gene discussed is BICC1; the disease is neoplasm.